Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis-Reference-Cited by-全球学者库

Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis

Published:2019-10-02 Issue:1 Volume:27 Page:45-51
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Rao Huiying¹,Song Guangjun²,Li Guangming³,Yang Yongfeng⁴,Wu Xiaofeng⁵,Guan Yujuan⁶,Mao Qing⁷,Jiang Xiangjun⁸,Wang Changyuan⁹,Zhang Ying¹⁰,Jia Jidong¹¹,Guo Xiaolin¹²,Li Chenghao¹³,Ning Jing¹⁴,Qin Hong¹⁴,Pan Hai¹⁴,Wei Lai¹⁵^ORCID

Affiliation:

1. Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease Peking University People’s Hospital Peking University Hepatology Institute Beijing China

2. Hepatology Department Peking University People’s Hospital Beijing China

3. Zhengzhou Municipal Sixth People's Hospital Zhengzhou China

4. Nanjing Municipal Second Hospital Nanjing China

5. Shenyang Municipal Sixth People's Hospital Shenyang China

6. Guangzhou Municipal Eighth People's Hospital Guanzhou China

7. Chinese PLA Third Military Medical University First Affiliated Hospital Chongqing China

8. Qingdao Municipal Hospital Qingdao China

9. Ji'nan Municipal Hospital of Infectious Disease Ji'nan Shandong China

10. Dalian Municipal Sixth People's Hospital Dalian China

11. Capital Medical University Affiliated Beijing Friendship Hospital Beijing China

12. Jilin University First Hospital Changchun China

13. Yanbian University Affiliated Hospital Yanji China

14. Beijing Kawin Technology Share‐holding Co., Ltd. Beijing China

15. Hepatopancreatobiliary Center Beijing Tsinghua Changgung Hospital Tsinghua University Beijing China

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13208

Reference11 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

2. Distribution and clinical correlates of viral and host genotypes in C hinese patients with chronic hepatitis C virus infection

3. APASL consensus statements and recommendation on treatment of hepatitis C

4. The guideline of prevention and treatment for hepatitis C: a. update;Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association;Zhonghua Gan Zang Bing Za Zhi,2015

5. Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: A systematic review and meta-analysis;2023-03-31

2. Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients;Virus Research;2021-09

3. Development of Validated Stability-indicating RP-HPLC Method for Determination of Novel Directly Acting Antiviral agent and Characterization of its Degradants by LC–ESI–MS;Indian Journal of Pharmaceutical Education and Research;2020-12-22

4. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single‐arm, open‐label, phase 3 trial;Liver International;2020-10-13